TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38369805
Drug: Salvage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage therapy in patients with extramedullary disease at baseline
Study: 38371290
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg inclisiran sodium on days 1, 90, and 270
Study: 38371314
Drug: octocog alfa
Normalized name: Octocog alfa
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: octocog alfa (on-demand therapy)
Study: 38371479
Drug: Dulaglutide 1.5
Normalized name: dulaglutide 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 1.5 mg subcutaneously once weekly for 12 weeks
Study: 38371479
Drug: Placebo subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneously once weekly for 12 weeks
Study: 38372621
Drug: Double-dose dolutegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose dolutegravir (50 mg twice daily)
Study: 38372621
Drug: Standard-dose dolutegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose dolutegravir
Study: 38372621
Drug: Double-dose dolutegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose dolutegravir
Study: 38372622
Drug: Propafenone (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (70 mg bolus followed by 400-840 mg/24 h)
Study: 38372622
Drug: Amiodarone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (300 mg bolus followed by 600-1800 mg/24 h)
Study: 38372727
Drug: Cadonilimab 15
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 15 mg/kg every 3 weeks plus chemotherapy
Study: 38372727
Drug: Cadonilimab 10
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy
Study: 38372727
Drug: Cadonilimab 10
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy and bevacizumab
Study: 38372727
Drug: Cadonilimab 10
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab 10 mg/kg every 3 weeks plus chemotherapy and bevacizumab (combined with cohort A-10)
Study: 38372727
Drug: Cadonilimab combined
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab combined with standard therapy
Study: 38372904
Drug: Everolimus (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (oral daily for 52 weeks)
Study: 38372938
Drug: GSK2982772 (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 (960 mg once-daily modified-release formulation)
Study: 38372949
Drug: PY314 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PY314 10 mg/kg in combination with pembrolizumab 200 mg IV every 21 days
Study: 38372981
Drug: Sublingual edaravone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual edaravone dexborneol (edaravone, 30 mg; dexborneol, 6 mg)
Study: 38372981
Drug: Placebo (edaravone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (edaravone, 0 mg; dexborneol, 60 μg)
Study: 38373857
Drug: Early Detection
Normalized name: Leader Early Detection Pregnancy Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Detection and Treatment to Reduce Events with Agitation Tool (ED-TREAT)
Study: 38374026
Drug: Post-transplantation cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplantation cyclophosphamide (PTCy) 50 mg/kg/d at days +3 and +4 plus standard GVHD prophylaxis
Study: 38374026
Drug: Anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thymocyte globulin (ATG) 5 mg/kg plus standard GVHD prophylaxis
Study: 38374062
Drug: Metronomic trabectedin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic trabectedin combined with low-dose cyclophosphamide
Study: 38374347
Drug: Nivolumab 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 480 mg every 4 weeks and regorafenib 80 mg daily (3-weeks-on/1-week-off schedule)
Study: 38375038
Drug: Remimazolam combined
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam combined with low dose esketamine
Study: 38375038
Drug: Propofol combined
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol combined with low dose esketamine
Study: 38375429
Drug: Inhaled APN01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled APN01 (rhACE2)
Study: 38375580
Drug: Treatment-as-usual (n=12)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (n=12)
Study: 38375995
Drug: Lacosamide (8-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (8-12 mg/kg/day)
Study: 38376229
Drug: Posaconazole intravenous
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole intravenous (IV) and powder for oral suspension (PFS) formulations at dosing regimens of 3.5, 4.5, and 6 mg/kg
Study: 38376229
Drug: Posaconazole 300
Normalized name: posaconazole 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole 300 mg/day tablet in a virtual adolescent population (body weight >40 kg)
Study: 38376591
Drug: Seawater nasal
Normalized name: Sodium Chloride 2600 mg in 100 mL NASAL SPRAY [NasalAsalt All-Natural Seawater]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seawater nasal wash (4-daily nasal washes with undiluted isotonic seawater)
Study: 38376596
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel (HyA)
Study: 38376645
Drug: Zonisamide 25
Normalized name: zonisamide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 25 mg
Study: 38376645
Drug: Zonisamide 50
Normalized name: zonisamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 50 mg
Study: 38376643
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) + topical timolol-dorzolamide eye drops
Study: 39446746
Drug: Facilitated directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated directly observed therapy (DOT)
Study: 39446746
Drug: Facilitated self-administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facilitated self-administered therapy (SAT)
Study: 38377520
Drug: Fluoxetine; dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine; dosage and duration not available
Study: 38377526
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment without pharmacogenetic testing)
Study: 38377775
Drug: Matched targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched targeted therapy
Study: 38377775
Drug: Non-matched treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-matched treatment
Study: 38377775
Drug: Matched targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched targeted therapy outside a clinical trial
Study: 38377773
Drug: TLD-1 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLD-1 administered intravenously every 3 weeks up to a maximum of 9 cycles (6 for patients with prior anthracyclines) starting dose of 10 mg/m², maximum administered dose of 45 mg/m², RP2D defined at 40 mg/m².
Study: 38377869
Drug: Simvastatin add-on
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin add-on treatment
Study: 38378522
Drug: Collagen patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen patch cover (CPC)
Study: 38378568
Drug: Kefir administration
Normalized name: Lentilactobacillus kefiri
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kefir administration (60 mL, followed by 120 mL after 12 h, then 240 mL daily)
Study: 38378568
Drug: Kefir administration
Normalized name: Lentilactobacillus kefiri
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kefir administration
Study: 38378678
Drug: Denosumab (RANKL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (RANKL inhibitor)
Study: 38378735
Drug: Evidence-based therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based therapies (EBTs) including antithrombotic drugs
Study: 38378937
Drug: Remimazolam besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam besylate loading dose
Study: 38380420
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg/Amlodipine 5 mg/Rosuvastatin 10 mg (TEL/ALD/RSV)
Study: 38380420
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/Atorvastatin 10 mg (ALD/ATV)
Study: 38380699
Drug: L-serine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-serine treatment for 52 weeks
Study: 38380779
Drug: Thin buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin buccal bone group
Study: 38380779
Drug: Thick buccal
Normalized name: tick-borne encephalitis purified antigen Prefilled Syringe [Ticovac]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thick buccal bone group
Study: 38380807
Drug: Acyclic retinoid
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclic retinoid (ACR) treatment for 4 weeks
Study: 38380940
Drug: Standard initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard initiation of Renal Replacement Therapy (RRT)
Study: 38380940
Drug: Accelerated initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Accelerated initiation of Renal Replacement Therapy (RRT)
Study: 38381068
Drug: Recreational drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational drug users (41 patients, 12.6% positive multidrug test)
Study: 38381068
Drug: Recreational drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational drug users
Study: 38381068
Drug: Non-recreational drug
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-recreational drug users (control group)
Study: 38381283
Drug: Pulmonary hypertension
Normalized name: Alyq 20 MG Pulmonary Hypertension Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary hypertension (PH)-targeted therapy
Study: 39661372
Drug: Pitavastatin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (4 mg per day)
Study: 38381417
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture (1-hour sessions, twice weekly for 15 weeks, up to 24 sessions)
Study: 38381417
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture (minimal needling, 1-hour sessions, twice weekly for 15 weeks, up to 24 sessions)
Study: 38381476
Drug: Internet-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-Based Cognitive Behavioral Therapy (ICBT)
Study: 38381664
Drug: Seladelpar (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seladelpar (10 mg daily)
Study: 38381752
Drug: Community delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community delivery of antiretroviral therapy (ART)
Study: 38381905
Drug: Micronized/ultramicronized palmitoylethanolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized/ultramicronized palmitoylethanolamide (m/umPEA) 600 mg twice daily for 3 months
Study: 38381905
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (did not accept m/umPEA therapy)
Study: 38381930
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drug in combination with paracetamol for 3 weeks
Study: 38383005
Drug: Preemptive IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive IV acetaminophen 15 mg/kg after anesthetic induction/before surgical incision
Study: 38383005
Drug: Preventive IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive IV acetaminophen 15 mg/kg at the end of surgery/before skin closure
Study: 38383268
Drug: Low-pressure hyperbaric
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-pressure hyperbaric oxygen therapy (HBOT), 8-week intervention (5 sessions per week)
Study: 38790008
Drug: Opioid maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid maintenance treatment (OMT)
Study: 38383367
Drug: Ivermectin (IVM)
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin (IVM) - 3 months of treatment
Study: 38383367
Drug: Dihydroartemisinin-piperaquine (DHP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DHP) - 3 months of treatment
Study: 38383426
Drug: Digital psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital psychological self-care (DPSC) with mid-treatment interview guidance
Study: 38383426
Drug: Digital psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital psychological self-care (DPSC) with weekly written messages guidance
Study: 38383462
Drug: Liraglutide (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (daily injections for at least 13 weeks before and 52 weeks after AF ablation)
Study: 38383476
Drug: Low-sodium bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium bread (280 mg Na/100 g) in Group C
Study: 38383476
Drug: Standard bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bread (750 mg Na/100 g) in Group A
Study: 38383578
Drug: AKS-452 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKS-452 (90 µg subcutaneous booster dose)
Study: 38384123
Drug: Radial shockwave
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shockwave therapy (RSWT) - five treatments (one week apart over five-week period) to the three most painful areas (500 shocks at 1.5 bar and 15 Hz, then 1000 shocks at 2 bar and 8 Hz, and finally 500 shocks at 1.5 bar and 15 Hz)
Study: 38384390
Drug: Exposure-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based therapy (EXP)
Study: 38384458
Drug: Intracranial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracranial infusion of TMZ-resistant γδ T cells (genetically engineered with p140K/MGMT lentivector)
Study: 38384458
Drug: Drug Resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Resistance Immunotherapy (DRI) combining TMZ and TMZ-resistant γδ T cells
Study: 38384801
Drug: UV1 vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV1 vaccination in combination with pembrolizumab
Study: 38384801
Drug: Pembrolizumab as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab as a single agent
Study: 38385243
Drug: Chlorambucil plus
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil plus subcutaneous rituximab induction and maintenance
Study: 38385243
Drug: Subcutaneous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous rituximab maintenance
Study: 38385566
Drug: mRNA-1345 (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1345 (12.5, 25, 50, 100, or 200 µg)
Study: 38385566
Drug: mRNA-1345 (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1345 (first injection)
Study: 38385587
Drug: Fenofibrate (145
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (145 mg tablet daily or on alternate days for those with impaired renal function)
Study: 38386178
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg every 8 weeks (Q8W)
Study: 38386266
Drug: Preoperative 1
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative 1 mg dexamethasone suppression test
Study: 38386376
Drug: Availability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Availability of information on diagnosis, current medication, test results, and risk scores
Study: 38386434
Drug: Community-Derived Open-Source
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-Derived Open-Source Automated Insulin Delivery Loop System
Study: 38386438
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine 300 U/mL
Study: 38386505
Drug: Single intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection of GMP manufactured stromal vascular fraction (SVF)
Study: 38386949
Drug: Zagotenemab 1,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zagotenemab 1,400 mg
Study: 38386949
Drug: Zagotenemab 5,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zagotenemab 5,600 mg
Study: 38386978
Drug: rilzabrutinib 400
Normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilzabrutinib 400 mg twice daily
Study: 38387470
Drug: Hepatitis E
Normalized name: hepatitis E vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis E vaccine (three doses administered intramuscularly at month 0, month 1, and month 6)
Study: 38387470
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three doses administered intramuscularly at month 0, month 1, and month 6)
Study: 38387597
Drug: 38% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% silver diamine fluoride (SDF) treatment applied once per week for 3 weeks
Study: 38387597
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment applied once per week for 3 weeks
Study: 38387978
Drug: Data collection
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data collection from ICU treatment for specific aspects of msTBI care.
Study: 38388017
Drug: Cooled radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooled radiofrequency (RF) treatment
Study: 38388017
Drug: Conventional radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiofrequency (RF) treatment
Study: 38388017
Drug: Cooled RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooled RF treatment in PPSP
Study: 38388017
Drug: Conventional RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional RF treatment in PPSP
Study: 38388017
Drug: Cooled RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooled RF treatment in OA
Study: 38388017
Drug: Conventional RF
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional RF treatment in OA
Study: 38388022
Drug: Smartphone game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Smartphone game intervention for HIV prevention; details on dosage and duration not available.
Study: 38388236
Drug: Booster shot
Normalized name: ChoreMate One-Shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster shot with Sabin inactivated poliomyelitis vaccine
Study: 38388646
Drug: Subcutaneous cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous cytarabine (100 mg/m2 for 5 days) administered in 35-day cycles for 12 total cycles
Study: 38388986
Drug: RBP-7000 (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBP-7000 (180 mg monthly injections)
Study: 38389078
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg once daily for 28 days (group A)
Study: 38390395
Drug: hyperbaric spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: hyperbaric spinal bupivacaine 0.5%, 1.3 ml (0.65 mg)
Study: 38390815
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (assessed by the insulin sensitivity index)
Study: 38391202
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using azacitidine and nivolumab (Aza/Nivo)
Study: 38391283
Drug: omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 fatty acid treatment
Study: 38391311
Drug: Quantitative US
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative US (QUS) radiomics data obtained after the 1st week of radiation therapy (RT)
Study: 38391311
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) with a total dose of 70 Gy in 33-35 fractions over 6-7 weeks
Study: 38393328
Drug: Benralizumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab (30 mg)
Study: 38393676
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel or ticagrelor for 5 days
Study: 39284337
Drug: Belzutifan 120
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belzutifan 120 mg once daily
Study: 38394048
Drug: Topical coconut-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical coconut-derived isosorbide diesters, dosage and duration not specified
Study: 38394048
Drug: Topical sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sunflower seed oil-derived isosorbide diesters, dosage and duration not specified
Study: 38394048
Drug: Vehicle control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control, dosage and duration not specified
Study: 38394113
Drug: Daily notification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily notification prompts for physical activity (PA)
Study: 38394387
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOAC) treatment with measurement of DOAC levels